biosimilars are coming:	
None of the industry watchers we spoke with was willing to say which	
drug maker is poised to lead the US biosimilars market. Some of the	
pending entrants	

Dissimilars are comingly

pending entrants	
COMPANY	BIOSIMILAR OF (INDICATION)
Amgen/Watson	Herceptin (cancer)

CUMPANY	BIOSIMILAR OF (INDICATION)
Amgen/Watson via Synthon	Herceptin (cancer)
me con	Location A.P. Location A.

via Synthon	nerceptiii (cancer)
Eli Lilly	Lantus (diabetes)

Eli Lilly	Lantus (diabetes)
Merck	Enbrel (rheumatoid arthritis)

Ell Lilly	Lantus (diabetes)
Merck	Enbrel (rheumatoid arthritis)
Morek	Cranulacyta colony stimulating factor

Merck	Enbrel (rheumatoid arthritis)
	Granulocyte colony stimulating factor
	(i.e., Neulasta; supportive cancer care)